Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
13
CANF Quote, Financials, Valuation and Earnings
Last price:
$0.18
Seasonality move
:
-4.6%
Day range:
$0.17 - $0.20
52-week range:
$0.23 - $2.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.34x
P/B ratio:
0.61x
Volume:
1.5M
Avg. volume:
13.5M
1-year change:
-87.39%
Market cap:
$2.8M
Revenue:
$677.2K
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.74 | 316.67% | -79.86% | $12.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
$0.18 | $3.25 | $2.8M | -- | $0.00 | 0% | 1.34x |
|
CGEN
Compugen Ltd.
|
$1.54 | $6.25 | $143.6M | 55.83x | $0.00 | 0% | 20.51x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
|
PLUR
Pluri, Inc.
|
$3.21 | $12.00 | $29.7M | -- | $0.00 | 0% | 17.55x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
|
PLUR
Pluri, Inc.
|
149.64% | 0.573 | 81% | 0.49x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
|
PLUR
Pluri, Inc.
|
-$15K | -$6.4M | -77.49% | -5662.45% | -2009.49% | -$5.5M |
Can-Fite BioPharma Ltd. vs. Competitors
-
Which has Higher Returns CANF or CGEN?
Compugen Ltd. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -369.06%. Can-Fite BioPharma Ltd.'s return on equity of -- beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About CANF or CGEN?
Can-Fite BioPharma Ltd. has a consensus price target of $3.25, signalling upside risk potential of 1251.35%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 311.18%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Compugen Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.2 0 0 CGENCompugen Ltd.4 0 0 -
Is CANF or CGEN More Risky?
Can-Fite BioPharma Ltd. has a beta of 0.982, which suggesting that the stock is 1.756% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock CANF or CGEN?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or CGEN?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Can-Fite BioPharma Ltd.'s net income of -- is lower than Compugen Ltd.'s net income of -$7M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 1.34x versus 20.51x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.1.34x -- -- -- CGENCompugen Ltd.20.51x 55.83x $1.9M -$7M
-
Which has Higher Returns CANF or NSRX?
Nasus Pharma has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of --. Can-Fite BioPharma Ltd.'s return on equity of -- beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- NSRXNasus Pharma-- -- -- -
What do Analysts Say About CANF or NSRX?
Can-Fite BioPharma Ltd. has a consensus price target of $3.25, signalling upside risk potential of 1251.35%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Can-Fite BioPharma Ltd. has higher upside potential than Nasus Pharma, analysts believe Can-Fite BioPharma Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.2 0 0 NSRXNasus Pharma0 0 0 -
Is CANF or NSRX More Risky?
Can-Fite BioPharma Ltd. has a beta of 0.982, which suggesting that the stock is 1.756% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CANF or NSRX?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or NSRX?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Nasus Pharma quarterly revenues of --. Can-Fite BioPharma Ltd.'s net income of -- is lower than Nasus Pharma's net income of --. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 1.34x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.1.34x -- -- -- NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns CANF or PHGE?
BiomX, Inc. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of --. Can-Fite BioPharma Ltd.'s return on equity of -- beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About CANF or PHGE?
Can-Fite BioPharma Ltd. has a consensus price target of $3.25, signalling upside risk potential of 1251.35%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe BiomX, Inc. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.2 0 0 PHGEBiomX, Inc.1 0 0 -
Is CANF or PHGE More Risky?
Can-Fite BioPharma Ltd. has a beta of 0.982, which suggesting that the stock is 1.756% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock CANF or PHGE?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or PHGE?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Can-Fite BioPharma Ltd.'s net income of -- is lower than BiomX, Inc.'s net income of -$9.2M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 1.34x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.1.34x -- -- -- PHGEBiomX, Inc.-- -- -- -$9.2M
-
Which has Higher Returns CANF or PLUR?
Pluri, Inc. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -1940.51%. Can-Fite BioPharma Ltd.'s return on equity of -- beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- PLURPluri, Inc.-4.75% -$0.65 $28.6M -
What do Analysts Say About CANF or PLUR?
Can-Fite BioPharma Ltd. has a consensus price target of $3.25, signalling upside risk potential of 1251.35%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 273.83%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Pluri, Inc., analysts believe Can-Fite BioPharma Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.2 0 0 PLURPluri, Inc.1 0 0 -
Is CANF or PLUR More Risky?
Can-Fite BioPharma Ltd. has a beta of 0.982, which suggesting that the stock is 1.756% less volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.476%.
-
Which is a Better Dividend Stock CANF or PLUR?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or PLUR?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $316K. Can-Fite BioPharma Ltd.'s net income of -- is lower than Pluri, Inc.'s net income of -$6.1M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 1.34x versus 17.55x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.1.34x -- -- -- PLURPluri, Inc.17.55x -- $316K -$6.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
